31 results about "Cellular Immunology" patented technology

The invention relates to the technical fields of molecular biology and cellular immunology and in particular relates to a preparation method of tumour cell specific polyclonal T cells. The preparation method of the tumour cell specific polyclonal T cells comprises the following steps: (1) obtaining peripheral blood mononuclear cells; (2) mixing the obtained peripheral blood mononuclear cells with gene modifying tumour cells; and (3) resuspending the obtained mixed cells in a culture medium containing cell factors which can maintain cell growth, proliferation and differentiation. The prepared tumour cell specific polyclonal T cells are mainly applied to medicines which are sued for preventing or treating cancers. The preparation method of the tumour cell specific polyclonal T cells has the advantages that the prepared tumour cell specific polyclonal T cells have the characteristics of large quantity, high specificity and strong killing capability; besides, a technology is simple, and the preparation cost is obviously reduced compared with the prior art.

The invention belongs to the technical field of cellular immunology and specifically discloses a special-purpose kit for preparing human dendritic cell vaccines capable of largely secreting IL(Interleukin)-12. The kit consists of a monocyte separating-obtaining culture medium, a culture medium for promoting DC (Dendritic Cell) to induce and differentiate, an agent for promoting the DC to mature and a tumor antigen. The DC prepared by the special-purpose kit disclosed by the invention is mainly applied to treating cancer patients or preventing cancer high-risk population. The special-purpose kit disclosed by the invention has the advantage that the prepared DC can secrete a great deal of IL-12, so that T cells are promoted to differentiate towards Th1 type immune response direction; and meanwhile, the special-purpose kit has the advantages of being simple in preparation process, low in cost, easy for large-scale production, and the like.

The invention belongs to the technology field of the cellular immunology, and particularly relates to a method for the dominant amplification of in vitro peripheral blood nature killer cells with a large amount. The method comprises the steps as follows: (1) separating single nucleus cell from human or animal peripheral blood; (2) suspending the single nucleus cell in an RPMI 1640 culture solution containing 5%-15% autologous serum and pretreating with methyl-Beta-cyclodextrin with an effective concentration of 1-4mmol/L for 36-60 hours; and (3) adding recombined interleukin 2, and amplification-culturing in an RPMI 1640 culture solution containing 5% of new-born calf serum and 5% of autologous serum for above 10 days. The method has the advantages that the blood sample amount is small; the cost is low; the operation is convenient; and the amplification multiple is high, and the nature killer cells can be amplified by 392-1752 times in a short term.

The invention belongs to the technical field of cell immunity, and particularly relates to a preparation method of a human D-CIK (dendritic cell activated and cytokine induced killer) cell with high toxicity and high value-adding capacity. The preparation method comprises the following steps of 1) collecting peripheral venous blood so as to obtain a single karyocyte; 2) further separating the single karyocyte so as to obtain a mononuclear cell and a suspension cell; 3) induced differentiating the mononuclear cell to a mature DC (dendritic cell); 4) induced culturing CD3+CD8+CIK cells; 5) induced culturing the D-CIK cells so as to obtain a novel heterogeneity cell mass, i.e. D-CIK cells. Compared with the CIK cell, the value-adding activity and the cell toxic activity of the prepared D-CIK cell are stronger, and the prepared D-CIK cell also has the advantages of simple preparation process, low cost, and the like, and mass production is easy to realize. The prepared D-CIK cell is mainly used for treating cancer patients or preventing the cancer high-risk group.

The invention provides application of cistanche deserticola polysaccharides as a vaccine adjuvant. Through tests such as detecting OVA (ovalbumin) specific antibody titer and cellular immunological activity in mice sera by animal grouping and immunizing methods and ELISA (enzyme linked immunosorbent assay), results show that the cistanche deserticola polysaccharides can serve as the adjuvant of a protein vaccine, a nucleic acid vaccine, a polypeptide vaccine, an inactivated vaccine or a live attenuated vaccine, and are obviously superior to an aluminum adjuvant in immunoenhancement effect, little in side effect, wide in source and easy to produce, and a preparation process of the cistanche deserticola polysaccharides is simple, low in cost, high in yield and beneficial to large-scale production.

The invention relates to the technical field of biology, and discloses a tumor specific target and application thereof. The target amino acid sequence is SAKYGVRKF. The tumor specific target can implement extraneous effective amplification and activation of dendritic cells. The provided T lymphocyte has specific killing effects on tumors, and is a cellular immunotherapy technique which most conforms to the cellular immunology principle at present.

The invention relates to cytochemistry and cellular immunology, which are particularly used for observing a marine bivalve meiosis device through immunofluorescence microscopy. A sample can be observed after pre-treatment of fixing and the like, dyeing and flaking. The sample is fixed by phosphate buffered saline (PBS) of paraformaldehyde at a mass percentage concentration of 2 to 6 percent; then,permeabilization treatment and sealing treatment are performed sequentially; immunofluorescence dyeing is performed on sample spindle bodies, and fluorescence dyeing is performed on chromosomes withthe phosphate buffered saline containing propidium iodide of which the concentration is 5 to 20 mg of per liter; and the sample is flaked after dyeing for observation through fluorescence microscopy.The cytological immunofluorescence observation method is suitable for observing the spindle bodies and the chromosomes of the marine bivalve meiosis device synchronously, has the advantages of simpleand direct operation, high definition and high study efficiency, and is a qualitative, positioning and quantitative cytological immunofluorescence observation method which inosculates forms and functions.

The invention belongs to the technical field of cellular immunology, and particularly relates to a morphology and purity and immunophenotyping detection method of human (gamma)(delta)T cells, which is used for detecting the prepared human (gamma)(delta)T cells. The method comprises the following steps: preparing human (gamma)(delta)T cells; and performing morphological observation with a microscope and purity and immunophenotyping analysis with a flow cytometer. The method provided by the invention has the advantages that the (gamma)(delta)T cells obtained by the test have the characteristics of large quantity, high purity, strong cytotoxicity and the like so as to ensure that the prepared human (gamma)(delta)T cells can meet the clinical needs; and moreover, the effects that the culture cost is greatly reduced from the non-peptide phosphate antigens such as IPP and the irritants such as anti-TCR (gamma)(delta) antibody are realized and the problems of small quantity, low toxicity, high cost and the like of in-vitro culture of (gamma)(delta)T cells in the prior art are solved.

The invention provides application of alpine yarrow herb polysaccharide as a vaccine adjuvant. Through an animal grouping and immune method, ELISA testing of titer and cellular immunological activity of an anti-OVA specific antibody in mouse sera and other experiments, results prove that the alpine yarrow herb polysaccharide can serve as an adjuvant for protein vaccines or polypeptide vaccines or inactivated vaccines or attenuated live vaccines or nucleic acid vaccines, and the immunological enhancement effect of the alpine yarrow herb polysaccharide is obviously better than that of an aluminum adjuvant. The alpine yarrow herb polysaccharide has the advantages of being small in side effect, wide in source and easy to produce. Moreover, the preparation process of the alpine yarrow herb polysaccharide is simple, cost is low, yield is high, and large-scale production is facilitated.

Embodiments of the invention provide a cell immunological assay kit used for evaluating the efficacy of a vaccine on the aspect of cell immunology and a method for storing the cell immunological assay kit. Some embodiments of the invention comprise a MHC-restricted viral antigenic peptide. Further, in some embodiments, the kit may use a vaccine research database of clinical trials and samples which are utilized in the therapeutic and conduct comprehensive testing on immune cells secrete cytokines by flow cytometry to establish a cellular immunology evaluation system. The kit may have a good storage stability and, in particular embodiments, the kit may provide a stability that maintains more than 90% of a material stored therein over a year or more.

The present invention relates to a method for diagnosing Lyme disease in a subject, the method comprising the steps of: (a) obtaining a sample from said subject, (b) contacting said sample with a source of Borrelia antigens and (c) determining the expression level of a pro-inflammatory cytokine in said sample at the end of step (b).

The invention discloses a mycobacterium tuberculosis Rv 2991 recombinant protein, a preparation method and application of the mycobacterium tuberculosis Rv 2991 recombinant protein. The mycobacterium tuberculosis Rv 2991 recombinant protein disclosed by the invention has an amino acid sequence shown as SEQ ID NO. 1. The invention also provides the preparation method of a coded nucleotide sequence of the mycobacterium tuberculosis Rv 2991 recombinant protein and the recombinant protein. Based on a research result of immunomics, a mycobacterium tuberculosis immunodominant antigen Rv 2991 is reported for the first time. By applying the mycobacterium tuberculosis Rv 2991 recombinant protein to a tuberculosis cellular immunology diagnosis, higher sensitivity is achieved, and the recombinant protein has the advantages of higher speed, safety and reliability in comparison with a conventional skin test.

The invention relates to the field of biotechnology, and discloses a virus specific target and an application thereof. The amino acid sequence of the hepatitis B virus specific target is FCWEWASAK. The invention further provides an application of the target in preparation of a preparation for treating hepatitis B related diseases. The target disclosed by the invention can realize in vitro effective amplification and activation of dendritic cells, the submitted T lymphocytes have specific killing effect to the virus, and the virus specific target is the cellular immunotherapy meeting the cellular immunology principle furthest, so the virus specific target has excellent application prospect.